Saxena AR, et al. | 2021, June 14 | Pfizer
https://pubmed.ncbi.nlm.nih.gov/34127852/
Research summary
This study evaluates the safety, tolerability, pharmacokinetics, and pharmacodynamics of Danuglipron, an oral small-molecule GLP-1 receptor agonist, in patients with type 2 diabetes. The research assesses the potential of Danuglipron to improve glycemic control through multiple ascending doses.
Key outcome of the study
Danuglipron was generally well-tolerated and demonstrated dose-dependent improvements in glycemic control, including reductions in fasting plasma glucose and even a decline in body weight. These findings support further investigation of Danuglipron as a potential oral therapy for type 2 diabetes and obesity.
Mouse model generated by genOway
The preclinical phase utilized a humanized GLP-1 receptor (hGLP-1R) knock-in mouse model developed by genOway. This model expresses the human GLP-1 receptor, enabling the evaluation of human-specific interactions and the pharmacodynamic profile of Danuglipron in vivo.
Danuglipron (PF-06882961) in Type 2 Diabetes: A Randomized, Placebo-Controlled, Multiple Ascending-Dose Phase 1 Trial
Get in touch about
Let us know how we can help
Scientific excellence
From model design to experimental results
Featured in 600+ scientific articles
Collaborative approach
Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions
Robust validation data on catalog models
Generated with biopharma partners and in-house
Innovative technologies
and guaranteed freedom to operate
Easy access to models
Models with certified health status from professional breeders in US and Europe